Bristol Myers Squibb (BMY) closed the most recent trading day at $60.48, moving +2.99% from the previous trading session. The stock outpaced the S&P 500’s daily loss of 0.51%. At the same time, the Dow lost 0.2%, and the tech-heavy Nasdaq lost 1.47%. <\/p>\n
Heading into today, shares of the biopharmaceutical company had gained 6.22% over the past month, outpacing the Medical sector’s gain of 3.63% and the S&P 500’s gain of 0.53%. <\/p>\n
The upcoming earnings release of Bristol Myers Squibb will be of great interest to investors. The company’s earnings report is expected on July 30, 2026. The company is forecasted to report an EPS of $1.59, showcasing a 8.9% upward movement from the corresponding quarter of the prior year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $11.67 billion, down 4.87% from the year-ago period. <\/p>\n
For the full year, the Zacks Consensus Estimates are projecting earnings of $6.34 per share and revenue of $47.47 billion, which would represent changes of +3.09% and -1.5%, respectively, from the prior year. <\/p>\n
Investors should also take note of any recent adjustments to analyst estimates for Bristol Myers Squibb. These recent revisions tend to reflect the evolving nature of short-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability. <\/p>\n
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To take advantage of this, we’ve established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system. <\/p>\n
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, there’s been a 0.31% rise in the Zacks Consensus EPS estimate. Bristol Myers Squibb is currently a Zacks Rank #3 (Hold). <\/p>\n
Looking at valuation, Bristol Myers Squibb is presently trading at a Forward P\/E ratio of 9.26. This denotes a discount relative to the industry average Forward P\/E of 18.95. <\/p>\n
It is also worth noting that BMY currently has a PEG ratio of 0.17. This metric is used similarly to the famous P\/E ratio, but the PEG ratio also takes into account the stock’s expected earnings growth rate. The average PEG ratio for the Medical – Biomedical and Genetics industry stood at 1.52 at the close of the market yesterday. <\/p>\n","protected":false},"excerpt":{"rendered":"Bristol Myers Squibb (BMY) closed the most recent trading day at $60.48, moving +2.99% from the previous trading…\n","protected":false},"author":2,"featured_media":1095366,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[8818],"tags":[381,23890,748,393,4884,299025,14413,16,15,23946],"class_list":["post-1095365","post","type-post","status-publish","format-standard","has-post-thumbnail","category-bristol","tag-bristol","tag-bristol-myers-squibb","tag-britain","tag-england","tag-great-britain","tag-medical-sector","tag-sp-500","tag-uk","tag-united-kingdom","tag-zacks-rank"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/116936784449596998","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/1095365","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=1095365"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/1095365\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/1095366"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=1095365"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=1095365"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=1095365"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}